Cancer Letters · 2017 · 128 citations · 37 references
MedicineOncologyPharmacologyImmunotherapyMolecular OncologyMolecular PharmacologyCancer ImmunotherapyMtor Inhibitor TherapyPancreatic CancerPancreatic DiseasesPancreatic DisordersBromodomain InhibitionBromodomain Protein TargetingBromodomain ProteinsPancreatic Cancer Pharmacotherapy
37
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy, Françoise Desseigne, Marc Ychou et al. · New England Journal of Medicine · 2011 · 7.8K citations · Full text
Medicine, Oncology, Pharmacology +13
Selective inhibition of BET bromodomains
P. Filippakopoulos, Jun Qi, S. Picaud et al. · Nature · 2010 · 4.3K citations · Full text
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Siân Jones, D. Williams Parsons, Jimmy Lin et al. · Science · 2008 · 4K citations · Full text
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake Delmore, Ghayas C. Issa, Madeleine E. Lemieux et al. · Cell · 2011 · 2.8K citations · Full text